These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 28902178

  • 1. Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.
    Park H, Kim D, Kim E, Sa JK, Lee HW, Yu S, Oh J, Kim SH, Yoon Y, Nam DH.
    Int J Mol Sci; 2017 Sep 13; 18(9):. PubMed ID: 28902178
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody.
    Park H, Kim D, Son E, Shin S, Sa JK, Kim SH, Yoon Y, Nam DH.
    Biochem Biophys Res Commun; 2017 Dec 09; 494(1-2):409-415. PubMed ID: 28917835
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y, Chen Y, Ding G, Wang M, Wu H, Xu L, Rui X, Zhang Z.
    Biochem Biophys Res Commun; 2015 Aug 14; 464(1):154-60. PubMed ID: 26093299
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
    Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P.
    Cancer Res; 2015 Aug 15; 75(16):3373-83. PubMed ID: 26141862
    [Abstract] [Full Text] [Related]

  • 9. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.
    van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK.
    Neoplasia; 2009 Apr 15; 11(4):355-64. PubMed ID: 19308290
    [Abstract] [Full Text] [Related]

  • 10. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.
    Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ, Jung S, Choi J, Lee S, Cheong KH, Kim DU, Park HW, Han YK, Kim GW, Choi H, Song PH, Kim KA.
    Oncogene; 2014 Jan 02; 33(1):34-43. PubMed ID: 23208509
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
    Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I, Pestova E, Anderson M, Pappano WN, Ansell P, Bhathena A, Naumovski L, Corvaia N, Reilly EB.
    BMC Cancer; 2016 Feb 16; 16():105. PubMed ID: 26879245
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
    Kou J, Musich PR, Staal B, Kang L, Qin Y, Yao ZQ, Zhang B, Wu W, Tam A, Huang A, Hao HX, Vande Woude GF, Xie Q.
    J Transl Med; 2018 Sep 12; 16(1):253. PubMed ID: 30208970
    [Abstract] [Full Text] [Related]

  • 17. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J, Wen W, Xiang D, Yin P, Liu Y, Liu C, He G, Cheng Z, Yin J, Sheng C, Zhang W, Nan F, Ye W, Zhang X, Wang H.
    Oncotarget; 2015 May 10; 6(13):11627-39. PubMed ID: 25890498
    [Abstract] [Full Text] [Related]

  • 18. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L, Li C, Zhu Y.
    Oncotarget; 2015 Oct 06; 6(30):30088-101. PubMed ID: 26254225
    [Abstract] [Full Text] [Related]

  • 19. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS.
    Cancer Lett; 2013 May 10; 332(1):74-82. PubMed ID: 23348694
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.